The effect of five different administration intervals on the pharmacokinetics (pk) of paclitaxel (PTX) and pegylated liposomal doxorubicin (PLD) association regimen

被引：0
|
作者：
Airoldi, M.
Cattel, L.
Passera, R.
Milla, P.
Cerutti, E.
Pedani, F.
Zanon, C.
Crova, A.
机构：
[1] S Giovanni Antica Sede Hosp, Turin, Italy
[2] Univ Torino, Turin, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
13012
引用
收藏
页数：2
相关论文
共 17 条
  • [11] Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pegylated liposomal doxorubicin (PLD) pharmacokinetics (PK) in patients with recurrent ovarian cancer.
    Caron, W. P.
    Lay, J. C.
    Fong, A. M.
    La-Beck, N. M.
    Newman, S. E.
    Clarke-Pearson, D. L.
    Brewster, W. R.
    Van Le, L.
    Bae-Jump, V. L.
    Gehrig, P. A.
    Zamboni, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [12] PHARMACOKINETICS, EFFICACY AND TOXICITY OF DIFFERENT PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) FORMULATIONS IN PRECLINICAL MODELS: IS A CONVENTIONAL BIOEQUIVALENCE APPROACH SUFFICIENT TO ENSURE THERAPEUTIC EQUIVALENCE OF PLD PRODUCTS?
    Mamidi, R. N. V. S.
    Weng, S.
    Stellar, S.
    Wang, C.
    Yu, N.
    Tonelli, A. P.
    Kelley, M. F.
    Angiuoli, A.
    Fung, M.
    ANNALS OF ONCOLOGY, 2010, 21 : 57 - 57
  • [13] Relationship Between Complement Factors and CC Chemokines and the Pharmacokinetics (PK) and Pharmacodynamics (PD) of PEGylated Liposomal Doxorubicin (PLD) in Patients with Refractory Epithelial Ovarian Cancer (EOC)
    Song, G.
    Moore, S.
    Tarrant, T.
    Dobrovolskaia, M.
    Barrow, D.
    Kumar, P.
    Newman, S.
    Bae-Jump, V.
    Gehrig, P.
    Zamboni, W.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 39 - 40
  • [14] Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer.
    Caron, Whitney Paige
    Lay, John C.
    Kumar, Parag
    Fong, Alan M.
    La-Beck, Ninh My
    Newman, Suzanne E.
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Linda Van Le
    Bae-Jump, Victoria Lin
    Gehrig, Paola A.
    Zamboni, William
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [15] Technetium-99m sulfur colloid (TSC) as a phenotypic probe for the pharmacokinetics (PK) and pharmacodynamics (PD) of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC).
    Walsh, M. D.
    Giovinazzo, H.
    Sheikh, A.
    Ivanovic, M.
    Whitlow, A. B.
    Newman, S. E.
    La-Beck, N. M.
    Kowalsky, R. J.
    Zamboni, B. A.
    Clarke-Pearson, D. L.
    Brewster, W. R.
    Van Le, L.
    Bae-Jump, V. L.
    Gehrig, P. A.
    Zamboni, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [16] Technetium-99m Sulfur Colloid (TSC) as a phenotypic probe for predicting pharmacokinetics (PK) and palmar-plantar erythrodysesthesia (PPE) toxicity of PEGylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer (EOC)
    Giovinazzo, Hugh
    Kumar, Parag
    Sheikh, Arif
    Ivanovic, Marija
    Walsh, Mark D.
    Caron, Whitney P.
    Song, Gina
    Whitlow, Ann B.
    Newman, Suzanne E.
    La-Beck, Nihn
    Kowalsky, Richard J.
    Zamboni, Beth A.
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Le, LindaVan
    Bae-Jump, Victoria Lin
    Gehrig, Paola A.
    Zamboni, William C.
    PHARMACOTHERAPY, 2012, 32 (10): : E310 - E310
  • [17] Technetium-99m sulfur colloid (TSC) as a phenotypic probe for predicting pharmacokinetics (PK) and palmar-plantar erythrodysesthesia (PPE) toxicity of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC).
    Giovinazzo, Hugh
    Kumar, Parag
    Sheikh, Arif
    Ivanovic, Marija
    Walsh, Mark Doughty
    Caron, Whitney Paige
    Song, Gina
    Whitlow, Ann B.
    Newman, Suzanne E.
    La-Beck, Ninh My
    Kowalsky, Richard J.
    Zamboni, Beth A.
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Van Le, Linda
    Bae-Jump, Victoria Lin
    Gehrig, Paola A.
    Zamboni, William
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12